{"title":"Real-world lecanemab adoption in Japan 1 year after launch: Insights from 311 specialists on infrastructure and reimbursement barriers","authors":"Kenichiro Sato, Yoshiki Niimi, Ryoko Ihara, Atsushi Iwata, Kiyotaka Nemoto, Tetsuaki Arai, Shinji Higashi, Ataru Igarashi, Kensaku Kasuga, Haruhiko Akiyama, Shuichi Awata, Manabu Ikeda, Takeshi Iwatsubo","doi":"10.1002/alz.70652","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>Lecanemab was approved for early Alzheimer's disease in Japan, with ≈ 6000 patients treated in the first year post approval. This study explores real-world practices, challenges, and potential solutions.</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>We conducted an anonymized online survey of clinical specialists authorized to prescribe lecanemab, obtaining responses from 311 specialists who collectively treated 3259 patients with lecanemab.</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>A majority of respondents (79%) reported wait times of ≤ 3 months from first consultation to initial infusion. One fourth reported tight outpatient space and staffing and significantly lower capacity of treatment than anticipated. Safety concerns were limited, with amyloid imaging-related abnormality–related interruptions in 3.5%. More than half highly supported additional reimbursement for infusion-related services and insurance coverage for apolipoprotein E (<i>APOE</i>) testing.</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>Early access to lecanemab appears feasible, yet infrastructure and financial hurdles remain. Dedicated reimbursement and insurance coverage for <i>APOE</i> testing may be essential for ensuring safer, more accessible, and sustainable use of this therapy in Japan.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>Results from an online survey of 311 Japanese specialists prescribing lecanemab in its first year are reported.</li>\n \n <li>Majority of wait times from first consultation to initial infusion were 1 to 3 months.</li>\n \n <li>Tight affordability of infusion space and staffing was reported by one quarter.</li>\n \n <li>Establishing additional medical fee for infusion management was highly expected.</li>\n \n <li>Reimbursement of apolipoprotein E test in Japanese health insurance system was also demanded.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 10","pages":""},"PeriodicalIF":11.1000,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/alz.70652","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.70652","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
INTRODUCTION
Lecanemab was approved for early Alzheimer's disease in Japan, with ≈ 6000 patients treated in the first year post approval. This study explores real-world practices, challenges, and potential solutions.
METHODS
We conducted an anonymized online survey of clinical specialists authorized to prescribe lecanemab, obtaining responses from 311 specialists who collectively treated 3259 patients with lecanemab.
RESULTS
A majority of respondents (79%) reported wait times of ≤ 3 months from first consultation to initial infusion. One fourth reported tight outpatient space and staffing and significantly lower capacity of treatment than anticipated. Safety concerns were limited, with amyloid imaging-related abnormality–related interruptions in 3.5%. More than half highly supported additional reimbursement for infusion-related services and insurance coverage for apolipoprotein E (APOE) testing.
DISCUSSION
Early access to lecanemab appears feasible, yet infrastructure and financial hurdles remain. Dedicated reimbursement and insurance coverage for APOE testing may be essential for ensuring safer, more accessible, and sustainable use of this therapy in Japan.
Highlights
Results from an online survey of 311 Japanese specialists prescribing lecanemab in its first year are reported.
Majority of wait times from first consultation to initial infusion were 1 to 3 months.
Tight affordability of infusion space and staffing was reported by one quarter.
Establishing additional medical fee for infusion management was highly expected.
Reimbursement of apolipoprotein E test in Japanese health insurance system was also demanded.
期刊介绍：
Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
